Lodonal™ Expected to Receive International Exposure at the World Health Assembly, one of the World’s Leading Health Forums
ORLANDO, Fla., May 18, 2016 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biotech company providing immunotherapy solutions for the treatment of infectious and non-infectious diseases, such as HIV/AIDS and cancer, with a focus on emerging nations, today announced its attendance at the 69th World Health Assembly (“WHA”) in Geneva, Switzerland to promote LodonalTM.
The WHA is the decision-making body of the World Health Organization (“WHO”). It is attended by delegations from all WHO member states and focuses on a specific health agenda prepared by the executive board. The main functions of the WHA are to determine the policies of the organization, appoint the Director-General, supervise financial policies, and review and approve the proposed programme budget (www.who.int/mediacentre/events/2016/wha69/en/).
In association with The Business Council for International Understanding (BCIU) and GB Pharma Holdings, Immune Therapeutics, Inc. (“Immune Therapeutics”) is hosting a welcome reception on Monday, May 23rd in Geneva, Switzerland at the WHA. Guests will include leadership from the U.S. & Foreign Health Delegations and Corporate Stakeholders. During and following this event, Immune Therapeutics and GB Pharma Holdings will focus on engaging with the heads of delegations representing primary targets for distribution of LodonalTM.
“Following successful achievement of two major milestones for LodonalTM in Nigeria this year, we are going to the WHA next week with momentum,” said Noreen Griffin, Chief Executive Officer of Immune Therapeutics.
Earlier this year Immune Therapeutics announced its clinical study in Nigeria. This study met primary and secondary endpoints for both efficacy and safety. On April 27th, Immune Therapeutics announced that Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC) approved LodonalTM as an over the counter, non-toxic adjunct therapy in the treatment of HIV/AIDS and immune regulator. Immune Therapeutics’ Agent for all of Africa, GB Pharma Holdings, will be spearheading LodonalTM distribution in Africa.
Dr. Arikana Chihombori, the Chair of the African Union-African Diaspora Health Initiative (AU-ADHI), supports the initiative with LodonalTM and stated that “the WHA is an excellent platform to expose and position LodonalTM within the global health dialogue, present Immune Therapeutics’ progress in Nigeria and ambition to bring this economically sound and effective treatment to all in need in Africa.”
The WHA brings together one of the largest global gatherings of international policy makers, health professionals and political representatives to discuss all global health concerns. Dr. Gloria B. Herndon, President and CEO of GB Pharma Holdings, noted that “it is imperative that our initiative with LodonalTM is brought to the foreground of strategic discussions regarding global health.”
Forward Looking Statements
This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that some or all of the matters and transactions considered by Immune Therapeutics may not proceed as contemplated, and by all other matters specified in Immune Therapeutics’ filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. Immune Therapeutics does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in Immune Therapeutics’ filings with the Securities and Exchange Commission, including its recent periodic reports.
About Immune Therapeutics:
Immune Therapeutics is a biotechnology company working to combat chronic, life-threatening diseases through the activation and modulation of the body's immune system using its patented immunotherapy. Its products and immunotherapy technologies are designed to harness the power of the immune system to improve the treatment of cancer, infections such as HIV/AIDS, chronic inflammatory diseases, and autoimmune diseases.
Immune Therapeutics’ proprietary technology, therapies and patents include the treatment of a wide range of cancers. Its most advanced clinical programs involve immunotherapy with met-enkephalin (MENK) (sometimes referred to as opioid growth factor) and its Low Dose Naltrexone (LDN) product or LodonalTM, which have been shown to stimulate the immune system even in patients with advanced cancer.
Even though management considers any condition that results in altered-immune response a target for investigation, management will most likely pursue additional investigations for MENK and LDN as valuable candidates in the treatment of autoimmune states such as rheumatoid arthritis and multiple sclerosis; as an adjunct in cancer patients undergoing chemotherapy, radiation treatments or surgery; and as a complement to antibiotics in the treatment of a variety of infectious diseases, including patients with HIV/AIDS, in combination with retroviral drug therapy.
About TNI BioTech International, Ltd.:
TNI BioTech International, Ltd., a wholly-owned subsidiary of Immune Therapeutics, incorporated in the British Virgin Islands, is responsible for managing Immune Therapeutics’ international clinical development and marketing and distribution of therapies in emerging nations.
About GB Pharma Holdings:
GB Pharma Holdings is a Washington D.C. global pharmaceutical company with expertise in defining policies, facilitating approvals, distribution and cGMP (current Good Manufacturing Practices) and introducing innovative therapies to Africa. GB Pharma Holdings was established in order to be on the forefront of change and is dedicated to bringing cost effective and quality products to Africa. GB Pharma Holdings is able to link new technologies, science and education together to be a cause for good. Its core focus is twofold; manufacturing cGMP quality pharmaceuticals and helping existing government agencies develop testing and regulations to purge counterfeit and sub-potent products out of their respective countries.
Additionally, GB Pharma Holdings sources products directly from manufacturers able to provide quality pharmaceuticals and medical products. GB Pharma Holdings is able to provide pedigree of any products it provides. Quality of products it distributes is guaranteed through testing reports, closed loop network and meticulous tracking from acquisition to final delivery on every product it provides. GB Pharma Holdings has relationships with several universities in the United States and teaching Hospitals, which keeps it on the cutting edge of proven new trends and technologies. Additionally, GB Pharma Holdings have an excellent relationship with international agencies and regulatory bodies.
Contact: Amato and Partners, LLC Investor Relations Counsel 90 Park Avenue. 17th Floor New York, NY 10016 admin@amatoandpartners.com
